Long Term Metabolic and Inflammatory Effects of Second-Generation Antipsychotics: A Study in Mentally Disordered Offenders

被引:6
|
作者
Vassilopoulou, Emilia [1 ]
Efthymiou, Dimitris [2 ]
Papatriantafyllou, Evangelia [1 ]
Markopoulou, Maria [3 ]
Sakellariou, Efthymia-Maria [4 ]
Popescu, Alina Codruta [5 ]
机构
[1] Int Hellen Univ, Dept Nutr Sci & Dietet, Thessaloniki 57400, Greece
[2] Aristotle Univ Thessaloniki, Sch Med, Div Neurosci, Dept Psychiat, Thessaloniki 54124, Greece
[3] Psychiat Hosp Thessaloniki, Dept Forens Psychiat, Thessaloniki 56429, Greece
[4] Gen Univ Hosp, Psychiat Clin, Larisa 41110, Greece
[5] Iuliu Hatieganu Univ Med & Pharm, Dept Abil Human Sci, Cluj Napoca 400012, Romania
来源
JOURNAL OF PERSONALIZED MEDICINE | 2021年 / 11卷 / 11期
关键词
forensic psychiatry; antipsychotic drugs; metabolic disturbances; WEIGHT-GAIN; CARDIOMETABOLIC RISK; 1ST-EPISODE SCHIZOPHRENIA; DRUGS; ANTIDEPRESSANTS; ZIPRASIDONE; OLANZAPINE; QUETIAPINE; CLOZAPINE; LEPTIN;
D O I
10.3390/jpm11111189
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Mentally disordered offenders provided with forensic psychiatric care are often treated with second generation antipsychotic (SGA) medication and experience metabolic and inflammatory side effects. Aim: In this paper, we monitored the three-year fluctuation of selected anthropometric, biochemical, and inflammatory indices in forensic psychiatric patients receiving antipsychotic (AP) medication for more than five years, according to the type of AP. Methods: Thirty-five patients with psychotic disorders were classified into two groups based on the type of AP. Specifically: AP1, related to a lower risk, and AP2, related to an increased risk of weight gain (WG) and metabolic complications. Biochemical, hematological, anthropometric, blood pressure (BP), and medication data were retrieved from the individual medical files. Statistical analysis was performed with SPSS 23. Results: No significant differences in weight and glucose and cholesterol levels were observed, but patients taking AP2 more often needed drugs to control diabetes mellitus (DM), lipidemia, and cardiovascular disease (CVD). In those taking AP1, the mean HDL level decreased significantly over time (p < 0.05) and a higher proportion developed higher BP (52.9% of AP1 vs. 16.7% AP2). In the AP2 group the median level of C-reactive protein (CRP) (p < 0.001) and the white blood cell count (WBC) increased over the three years (p < 0.001). Conclusions: The proposed sub-classification of SGAs into AP1 and AP2, depending on their potential for metabolic and inflammatory effects, might facilitate study of their long-term side-effects but also help in personalized prevention or treatment measures to counteract these side-effects.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] Current and Novel Approaches to Mitigate Cardiometabolic Adverse Effects of Second-Generation Antipsychotics
    Skonieczna-Zydecka, Karolina
    Loniewski, Igor
    Stachowska, Ewa
    Marlicz, Wojciech
    Correll, Christoph U.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2020, 23 (08) : 491 - 495
  • [32] A controlled, mirror-image study of second-generation antipsychotics in the treatment of schizophrenia
    Taylor, David
    Hayhurst, Karen
    Kerwin, Robert
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2007, 22 (03) : 133 - 136
  • [33] Metabolic consequences of second-generation antipsychotics in youth: appropriate monitoring and clinical management
    Krill, Rebecca A.
    Kumra, Sanjiv
    ADOLESCENT HEALTH MEDICINE AND THERAPEUTICS, 2014, 5 : 171 - 182
  • [34] Long-Term Recidivism of Mentally Disordered Offenders Considered "Dangerous to the Public" in Switzerland
    Schaffner, Daniela
    Weber, Michael
    Kochuparackal, Tanya
    Graf, Marc
    Hachtel, Henning
    FRONTIERS IN PSYCHIATRY, 2021, 12
  • [35] Metabolic outcomes of bergamot polyphenolic fraction administration in patients treated with second-generation antipsychotics: a pilot study
    Bruno, Antonio
    Pandolfo, Gianluca
    Crucitti, Manuela
    Maisano, Antonino
    Zoccali, Rocco A.
    Muscatello, Maria Rosaria Anna
    JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 2017, 40 : 32 - 35
  • [36] Differences between men and women in side effects of second-generation antipsychotics
    Aichhorn, W.
    Whitworth, A. B.
    Weiss, E. M.
    Hinterhuber, H.
    Marksteiner, J.
    NERVENARZT, 2007, 78 (01): : 45 - +
  • [37] New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia
    Citrome, Leslie
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2013, 13 (07) : 767 - 783
  • [38] One-Year Prospective Study of Liver Function Tests in Children and Adolescents on Second-Generation Antipsychotics: Is There a Link with Metabolic Syndrome?
    Baeza, Inmaculada
    de la Serna, Elena
    Calvo-Escalona, Rosa
    Merchan-Naranjo, Jessica
    Rodriguez-Latorre, Pamela
    Carmen Martinez-Cantarero, M.
    Andres, Patricia
    Angel Alda, Jose
    Munoz-Samons, Daniel
    Ilzarbe, Daniel
    Arango, Celso
    Castro-Fornieles, Josefina
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2018, 28 (07) : 463 - 473
  • [39] Weight gain with add-on second-generation antipsychotics in bipolar disorder: a naturalistic study
    Najar, H.
    Joas, E.
    Kardell, M.
    Palsson, E.
    Landen, M.
    ACTA PSYCHIATRICA SCANDINAVICA, 2017, 135 (06) : 606 - 611
  • [40] Effects of Lithium Combined with Second-Generation Antipsychotics for the Treatment of Manic Episodes in Patients with Bipolar Disorder: A Naturalistic Study in China
    Liu, Yang
    Liang, Jun
    Xia, Qingrong
    Zhou, Xin
    Xie, Xuefeng
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2020, 16 : 2623 - 2632